Filana Therapeutics Stock Price, News & Analysis
Company Description
Filana Therapeutics, Inc. develops investigational biotechnology therapies focused on Tuberous Sclerosis Complex-related epilepsy. The company’s lead program centers on simufilam, a proprietary oral small molecule intended to modulate the filamin A protein. Filana Therapeutics trades on the Nasdaq Capital Market under the symbol FLNA and is headquartered in Austin, Texas.
The company’s current scientific focus is the relationship between filamin A biology and central nervous system disorders, including TSC-related epilepsy. Tuberous Sclerosis Complex is associated with neurological manifestations that can include epilepsy, and Filana Therapeutics is evaluating simufilam as a potential treatment approach within that disease context. The company has also described its broader interest in diseases associated with dysregulation or overexpression of filamin A.
Filana Therapeutics is a development-stage biotechnology company rather than a commercial drug manufacturer. Its business model is based on research and development, preclinical work, regulatory engagement, and clinical-development planning for investigational medicines. Company updates have described preclinical data for simufilam in a mouse model of severe TSC-related epilepsy, scientific presentations on the biological rationale for the program, and work related to regulatory requirements for advancing the program.
Program and technology focus
Simufilam is described by the company as an oral small molecule intended to modulate filamin A protein. The program is directed primarily toward TSC-related epilepsy, a central nervous system disorder area. Filana Therapeutics has reported preclinical findings in this indication and has presented scientific rationale for evaluating simufilam in TSC-related epilepsy.
The company’s development activities include preclinical studies, protocol design work, and regulatory interactions with the U.S. Food and Drug Administration. Its TSC-related epilepsy program has been subject to an FDA clinical hold, and company materials describe efforts to generate additional data and address regulator feedback. These activities place the company within the clinical-stage biotechnology category, where operating results are driven by research spending, development timelines, regulatory status, and financing resources rather than product revenue from approved therapies.
Corporate identity
Filana Therapeutics was formerly known as Cassava Sciences, Inc. The company announced its name change and new ticker symbol in 2026, aligning the corporate identity with its focus on filamin A modulation and TSC-related epilepsy. The FLNA ticker represents the renamed public company and its continuing biotechnology development activities.
As a public biotechnology issuer, Filana Therapeutics’ disclosures commonly address research progress, financial results, regulatory matters, corporate governance, compensation, board composition, and the risks inherent in drug discovery and development. Its operating profile is concentrated, with company-specific attention centered on simufilam, filamin A modulation, TSC-related epilepsy, and the regulatory path for investigational therapy development.
Stock Performance
Filana Therapeutics (FLNA) stock last traded at $1.18, down 1.27% from the previous close. Over the past 12 months, the stock has lost 43.5%. At a market capitalization of $57.5M, FLNA is classified as a micro-cap stock with approximately 48.3M shares outstanding.
FLNA Rankings
Latest News
Filana Therapeutics has 5 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 3 with negative movement. Key topics include earnings. View all FLNA news →
SEC Filings
Filana Therapeutics has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 10-Q, 1 Form ARS, 1 Form DEF 14A. The most recent filing was submitted on June 15, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all FLNA SEC filings →
Financial Highlights
operating income reached -$95.4M, and net income was -$91.0M. Diluted earnings per share stood at $-1.88. The company generated -$32.3M in operating cash flow. With a current ratio of 2.23, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Filana Therapeutics (FLNA) currently stands at 6.9 million shares, up 2.9% from the previous reporting period, representing 15.2% of the float. This moderate level of short interest indicates notable bearish positioning. With 16.8 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Filana Therapeutics (FLNA) currently stands at 16.8 days, up 14.5% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 86.8% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 9.0 to 22.4 days.
FLNA Company Profile & Sector Positioning
Filana Therapeutics (FLNA) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.